High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.

Joseph Andrew ClaraEmily R LevyRobert RegerStefan BarisicLong ChenElena CherkasovaMala ChakrabortyDavid S J AllanRichard Childs

Published in: Journal for immunotherapy of cancer (2022)

NK cells has the potential to boost the clinical efficacy of DARA. By incorporating complementary genetic engineering strategies into a CD38 KO manufacturing platform, we generated NK cells with substantially augmented CD38-directed antitumor activity, establishing a strong rationale for exploring this immunotherapy strategy in the clinic.

Keyphrases

nk cells
crispr cas
natural killer cells
genome editing
endothelial cells
primary care